KR

Karuna Therapeutics IncNASDAQ KRTX Stock Report

Last reporting period 31 Dec, 2023

Updated —

Last price

Market cap $B

12.599

Large

Exchange

XNAS - Nasdaq

KRTX Stock Analysis

KR

Uncovered

Karuna Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-29/100

Low score

Market cap $B

12.599

Dividend yield

Shares outstanding

37.002 B

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 210 full-time employees. The company went IPO on 2019-06-28. The firm is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. The company is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The firm is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. The company is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

View Section: Eyestock Rating